3 Specialty Export Formulations, Cardiac and CNS Leader and Contract Injectables Stocks With a Strong Future Roadmap: Rubicon Research, Torrent Pharmaceuticals and Gland Pharma
- October 22, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Rubicon Research, Torrent Pharmaceuticals and Gland Pharma: ROE of 9.9% to 25.5% and FY22 to FY26 revenue CAGR of 9.9% to 52.0%. Prices as of 21 Oct 2026.
Quick Answer
The three pharma exports and chronic care stocks to watch are Rubicon Research, Torrent Pharmaceuticals and Gland Pharma. Their return on equity ranges from 9.9% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.9% to 52.0%. Torrent Pharmaceuticals has the highest return on equity at 25.5%, while Rubicon Research has the fastest revenue growth at 52.0% a year. Prices are based on the 21 October 2026 close, and this article is educational, not investment advice.
Pharma exports and chronic care stocks let investors follow companies that earn from complex products abroad and long-term therapies at home. Rubicon Research, Torrent Pharmaceuticals and Gland Pharma cover specialty export formulations, a cardiac and central nervous system leader and contract injectables.
This list covers three pharma exports and chronic care stocks with complete current figures: Rubicon Research, Torrent Pharmaceuticals and Gland Pharma. Every figure comes from the latest reported financials and the 21 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pharma Exports and Chronic Care Stocks?
Pharma exports and chronic care stocks are listed pharmaceutical companies that sell specialty formulations and injectables overseas or lead in chronic therapies in India. Their earnings depend on approvals, launches and prescription trends.
Pharma Exports and Chronic Care Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Rubicon Research | 1,448.5 | 24,654 | 85.5 | 36.0 | 19.1 | 0.24 |
| Torrent Pharmaceuticals | 4,553.8 | 173,079 | 80.3 | 36.0 | 25.5 | 1.79 |
| Gland Pharma | 2,935 | 49,953 | 44.2 | 36.0 | 9.9 | 0.03 |
On valuation, all three trade at a P/E above their industry P/E, which reflects the growth the market already expects from them. Readers comparing pharma exports and chronic care stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in pharma exports and chronic care stocks can use the coming numbers to test whether growth is holding.
Why Do Pharma Exports and Chronic Care Stocks Have a Strong Roadmap in India?
Pharma exports and chronic care stocks have a strong roadmap in India because rising chronic disease at home and demand for differentiated medicines and injectables abroad support steady growth.
- Chronic disease burden. More patients need long-term heart and brain medication.
- Differentiated products. Specialty formulations earn better pricing than basic generics.
- Injectables demand. Hospitals need steady supplies of sterile products.
Why Rubicon Research Features Among These Pharma Exports and Chronic Care Stocks
Among the pharma exports and chronic care stocks on this list, Rubicon Research is a pharmaceutical formulations company that develops and sells specialty and complex generic products, with the United States as its main market.
In the June 2026 quarter, revenue grew 52.9% year on year to Rs 540 crore, while net profit rose 95.8% to Rs 84.8 crore. Revenue rose from Rs 330 crore in FY22 to Rs 1,762 crore in FY26, a compound annual growth rate of 52.0%.
Net profit grew from Rs 91.0 crore in FY24 to Rs 247 crore in FY26, which works out to a compound annual growth rate of 64.7%. The company has a return on equity of 19.1%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 24,654 crore. The stock trades at a P/E of 85.5, above the industry P/E of 36.0.
Roadmap: The company builds differentiated products that need technical skill and earn better pricing than basic generics. A growing list of approved products and an own-label model give it room to widen its portfolio.
What to watch: Follow new product approvals and launches in the United States.
Why Torrent Pharmaceuticals Features Among These Pharma Exports and Chronic Care Stocks
Among the cardiac and CNS pharma shares on this list, Torrent Pharmaceuticals is an Ahmedabad-based pharma company that leads in cardiovascular, central nervous system and gastro-intestinal therapies in India, with a growing presence in Brazil, Germany and the United States.
The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0.
Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore.
Roadmap: The company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.
What to watch: Watch the integration of newly acquired brands and the progress of margin improvement in the enlarged business.
Why Gland Pharma Features Among These Pharma Exports and Chronic Care Stocks
Among the three companies on this list, Gland Pharma is a Hyderabad-based maker of sterile injectable medicines and a leading contract manufacturer for global drug companies, with plants in India and Europe.
Revenue rose from Rs 4,625 crore in FY22 to Rs 6,747 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 781 crore in FY23 to Rs 1,027 crore in FY26, which works out to a compound annual growth rate of 9.6%.
In the June 2026 quarter, revenue grew 19.1% year on year to Rs 1,862 crore, while net profit rose 47.1% to Rs 317 crore. The company has a return on equity of 9.9%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 49,953 crore. The stock trades at a P/E of 44.2, above the industry P/E of 36.0.
Roadmap: Injectables are a segment where few suppliers have the technical and regulatory capability, and the company serves customers across more than 60 countries. Its partnerships with large marketers and its expanded European base support growth.
What to watch: Check new product launches and utilisation of its manufacturing capacity.
Rubicon Research vs Torrent Pharmaceuticals vs Gland Pharma on Key Financials
The table below sets the three pharma exports and chronic care stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Rubicon Research | 330 | 1,762 | 52.0% | 247 | 14.0% |
| Torrent Pharmaceuticals | 8,705 | 13,886 | 12.4% | 2,138 | 15.4% |
| Gland Pharma | 4,625 | 6,747 | 9.9% | 1,027 | 15.2% |
Torrent Pharmaceuticals posts the highest return on equity in this group at 25.5%. Torrent Pharmaceuticals has the largest FY26 revenue at Rs 13,886 crore, and Rubicon Research shows the fastest revenue growth with a 52.0% compound annual rate. A useful habit with pharma exports and chronic care stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Rubicon Research | 353 | 540 | 52.9% |
| Torrent Pharmaceuticals | 3,141 | 4,909 | 56.3% |
| Gland Pharma | 1,563 | 1,862 | 19.1% |
Key Risks to Check Before Investing in Pharma Exports and Chronic Care Stocks
Every theme carries risks that deserve a check before any decision. For these pharma exports and chronic care stocks, the main points are: Long-term cardiac and CNS pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Approval timelines. Launches depend on regulatory decisions that can shift.
- Pricing rules. Price controls can limit the pace of growth for some medicines.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter pharma exports and chronic care stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Pharma Exports and Chronic Care Stocks
Pharma exports and chronic care stocks reward investors who follow approvals, launches and prescription trends together. Rubicon Research, Torrent Pharmaceuticals and Gland Pharma each show a different route to growth. Based on the 21 October 2026 close, Rubicon Research trades at Rs 1,448.5, Torrent Pharmaceuticals at Rs 4,553.8 and Gland Pharma at Rs 2,935. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these pharma exports and chronic care stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track pharma exports and chronic care stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are pharma exports and chronic care stocks?
Ans. Pharma exports and chronic care stocks are listed pharmaceutical companies that sell specialty formulations and injectables overseas or lead in chronic therapies in India. Their earnings depend on approvals, launches and prescription trends. This list looks at three of them, Rubicon Research, Torrent Pharmaceuticals and Gland Pharma, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.
Which pharma exports and chronic care stocks are covered in this list?
Ans. This list covers Rubicon Research, Torrent Pharmaceuticals and Gland Pharma. Based on the 21 October 2026 close, Rubicon Research traded at Rs 1,448.5, Torrent Pharmaceuticals at Rs 4,553.8 and Gland Pharma at Rs 2,935. Their return on equity ranges from 9.9% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.9% to 52.0%.
Why do pharma exports and chronic care stocks have a strong future roadmap in India?
Ans. Pharma exports and chronic care stocks have a strong roadmap in India because rising chronic disease at home and demand for differentiated medicines and injectables abroad support steady growth. The main drivers are as follows. Chronic disease burden. More patients need long-term heart and brain medication. Differentiated products. Specialty formulations earn better pricing than basic generics. Injectables demand. Hospitals need steady supplies of sterile products. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Rubicon Research performed financially?
Ans. Revenue rose from Rs 330 crore in FY22 to Rs 1,762 crore in FY26, a compound annual growth rate of 52.0%. Net profit grew from Rs 91.0 crore in FY24 to Rs 247 crore in FY26, which works out to a compound annual growth rate of 64.7%. In the June 2026 quarter, revenue grew 52.9% year on year to Rs 540 crore, while net profit rose 95.8% to Rs 84.8 crore. The company has a return on equity of 19.1%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 24,654 crore. The stock trades at a P/E of 85.5, above the industry P/E of 36.0. Looking ahead, the company builds differentiated products that need technical skill and earn better pricing than basic generics. A growing list of approved products and an own-label model give it room to widen its portfolio.
How has Torrent Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.
How has Gland Pharma performed financially?
Ans. Revenue rose from Rs 4,625 crore in FY22 to Rs 6,747 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 781 crore in FY23 to Rs 1,027 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 19.1% year on year to Rs 1,862 crore, while net profit rose 47.1% to Rs 317 crore. The company has a return on equity of 9.9%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 49,953 crore. The stock trades at a P/E of 44.2, above the industry P/E of 36.0. Looking ahead, injectables are a segment where few suppliers have the technical and regulatory capability, and the company serves customers across more than 60 countries. Its partnerships with large marketers and its expanded European base support growth.
What risks should investors check before buying pharma exports and chronic care stocks?
Ans. Investors should check a few risks before buying pharma exports and chronic care stocks. Approval timelines. Launches depend on regulatory decisions that can shift. Pricing rules. Price controls can limit the pace of growth for some medicines. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of pharma exports and chronic care stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
